# US 2021/0070871 A1 · Optimized anti-tl1a antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0070871 A1
- Document ID: US20210070871A1
- Status: Published application
- Kind: A1
- Application number: 17/050,064
- Filed: 2019-04-24
- Published: 2021-03-11
- Earliest claimed: 2018-04-25
- Assignees: Prometheus Biosciences, Inc.
- Applicants: Prometheus Biosciences, Inc.
- Inventors: Jeffry D. WATKINS; Cindy T. DICKERSON; J. Monty WATKINS; Patricia MCNEELEY
- Web page: https://patentgrep.com/patent/US20210070871A1

## CPC

- C07K 16/24: against cytokines, lymphokines or interferons
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/241: {Tumor Necrosis Factors}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2875: {against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241)}
- C12N 5/10: Cells modified by introduction of foreign genetic material
- C12N 15/09: Recombinant DNA-technology
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/524: CH2 domain
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/90: characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohns Disease (CD) and ulcerative colitis (UC).

## Claims

### Claim 1

An antibody or antigen-binding fragment that specifically binds TL1A, comprising:
a heavy chain variable region comprising:
(a) an HCDR1 comprising an amino acid sequence set forth by SEQ ID NO: 553;
(b) an HCDR2 comprising an amino acid sequence set forth by any one of SEQ ID NOs: 554 to 564 or 574 to 577; and
(c) an HCDR3 comprising an amino acid sequence set forth by any one of SEQ ID NOs: 565 to 568 or 578 to 581; and
a light chain variable region comprising:
(d) an LCDR1 comprising an amino acid sequence set forth by any one of SEQ ID NOs: 569 or 570;
(e) an LCDR2 comprising an amino acid sequence set forth by SEQ ID NO: 488; and
(f) an LCDR3 comprising an amino acid sequence set forth by any one of SEQ ID NOs: 571 to 573 or 582 to 585.

### Claim 2 (depends on 1)

The antibody or antigen-binding fragment that specifically binds TL1A of claim 1, wherein:
(a) the HCDR1 comprises the amino acid sequence set forth by SEQ ID NO: 553;
(b) the HCDR2 comprises the amino acid sequence set forth by SEQ ID NO: 559;
(c) the HCDR3 comprises the amino acid sequence set forth by SEQ ID NO: 567;
(d) the LCDR1 comprises the amino acid sequence set forth by SEQ ID NO: 569;
(e) the LCDR2 comprises the amino acid sequence set forth by SEQ ID NO: 488; and
(f) the LCDR3 comprises the amino acid sequence set forth by SEQ ID NO: 573.

### Claim 3 (depends on 1)

The antibody or antigen-binding fragment that specifically binds TL1A of claim 1, wherein:
(a) the HCDR1 comprises the amino acid sequence set forth by SEQ ID NO: 553;
(b) the HCDR2 comprises the amino acid sequence set forth by SEQ ID NO: 563;
(c) the HCDR3 comprises the amino acid sequence set forth by SEQ ID NO: 568;
(d) the LCDR1 comprises the amino acid sequence set forth by SEQ ID NO: 569;
(e) the LCDR2 comprises the amino acid sequence set forth by SEQ ID NO: 488; and
(f) the LCDR3 comprises the amino acid sequence set forth by SEQ ID NO: 572.

### Claim 4 (depends on 1)

The antibody or antigen-binding fragment that specifically binds TL1A of claim 1, wherein:
(a) the HCDR1 comprises the amino acid sequence set forth by SEQ ID NO: 553;
(b) the HCDR2 comprises the amino acid sequence set forth by SEQ ID NO: 555;
(c) the HCDR3 comprises the amino acid sequence set forth by SEQ ID NO: 566;
(d) the LCDR1 comprises the amino acid sequence set forth by SEQ ID NO: 569;
(e) the LCDR2 comprises the amino acid sequence set forth by SEQ ID NO: 488; and
(f) the LCDR3 comprises the amino acid sequence set forth by SEQ ID NO: 572.

### Claim 5 (depends on 1)

The antibody or antigen-binding fragment that specifically binds TL1A of claim 1, wherein:
(a) the HCDR1 comprises the amino acid sequence set forth by SEQ ID NO: 553;
(b) the HCDR2 comprises the amino acid sequence set forth by SEQ ID NO: 558;
(c) the HCDR3 comprises the amino acid sequence set forth by SEQ ID NO: 566;
(d) the LCDR1 comprises the amino acid sequence set forth by SEQ ID NO: 569;
(e) the LCDR2 comprises the amino acid sequence set forth by SEQ ID NO: 488; and
(f) the LCDR3 comprises the amino acid sequence set forth by SEQ ID NO: 572.

### Claim 6 (depends on 1)

The antibody or antigen-binding fragment that specifically binds TL1A of claim 1, wherein:
(a) the HCDR1 comprises the amino acid sequence set forth by SEQ ID NO: 553;
(b) the HCDR2 comprises the amino acid sequence set forth by SEQ ID NO: 564;
(c) the HCDR3 comprises the amino acid sequence set forth by SEQ ID NO: 568;
(d) the LCDR1 comprises the amino acid sequence set forth by SEQ ID NO: 569;
(e) the LCDR2 comprises the amino acid sequence set forth by SEQ ID NO: 488; and
(f) the LCDR3 comprises the amino acid sequence set forth by SEQ ID NO: 572.

### Claim 7

An antibody or antigen-binding fragment that specifically binds TL1A, comprising: a heavy chain variable region comprising:
(a) an HCDR1, an HCDR2, and an HCDR3 selected from any one of SEQ ID NOs: 491, 493, 495, 497, 499, 501, 503, 505, 507, 509, 511, 513, 515, 517, 519, 521, 523, 525, 527, 529, 531, 533, 535, 537, 539, or 541; and
a light chain variable region comprising
(b) an LCDR1, an LCDR2, and an LCDR3 selected from any one of SEQ ID NOs: 490, 492, 494, 496, 498, 500, 502, 504, 506, 508, 510, 512, 514, 516, 518, 520, 522, 524, 526, 528, 530, 532, 534, 536, 538, or 540;
wherein the CDRs are defined by the Kabat, Chothia, or IMGT method or a combination thereof.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The antibody or antigen-binding fragment that specifically binds TL1A of any one of claims 1 to 7, comprising:
(a) a human heavy chain framework region 1 that is at least 95% identical to that set forth is SEQ ID NO: 545;
(b) a human heavy chain framework region 2 that is at least 95% identical to that set forth is SEQ ID NO: 546;
(c) a human heavy chain framework region 3 that is at least 95% identical to that set forth is SEQ ID NO: 547 or 586 to 588;
(d) a human heavy chain framework region 4 that is at least 95% identical to that set forth is SEQ ID NO: 548;
(e) a human light chain framework region 1 that is at least 95% identical to that set forth is SEQ ID NO: 549;
(f) a human light chain framework region 2 that is at least 95% identical to that set forth is SEQ ID NO: 550;
(g) a human light chain framework region 3 that is at least 95% identical to that set forth is SEQ ID NO: 551; and
(h) a human light chain framework region 4 that is at least 95% identical to that set forth is SEQ ID NO: 552.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The antibody or antigen-binding fragment that specifically binds TL1A of any one of claims 1 to 8, comprising a heavy chain variable region comprising an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 503, 511, 493, 501, or 515; and a light chain variable region comprising an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 502, 510, 492, 500, or 514.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The antibody or antigen-binding fragment that specifically binds TL1A of any one of claims 1 to 8, comprising a heavy chain variable region comprising an amino acid sequence set forth in any one of SEQ ID NOs: 503, 511, 493, 501, or 515; and a light chain variable region comprising an amino acid sequence set forth in any one of SEQ ID NOs: 502, 510, 492, 500, or 514.

### Claim 11

An antibody or antigen-binding fragment that specifically binds TL1A, comprising:
(a) a heavy chain variable region comprising an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 491, 493, 495, 497, 499, 501, 503, 505, 507, 509, 511, 513, 515, 517, 519, 521, 523, 525, 527, 529, 531, 533, 535, 537, 539, or 541; and
(b) a light chain variable region comprising an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 490, 492, 494, 496, 498, 500, 502, 504, 506, 508, 510, 512, 514, 516, 518, 520, 522, 524, 526, 528, 530, 532, 534, 536, 538, or 540.

### Claim 12 (depends on 11)

The antibody or antigen-binding fragment that specifically binds TL1A of claim 11, wherein the heavy chain variable region comprises an amino acid sequence at least about 90% identical to SEQ ID NO: 503; and wherein the light chain variable region comprises an amino acid sequence at least about 90% identical to SEQ ID NO: 502.

### Claim 13 (depends on 12)

The antibody or antigen-binding fragment that specifically binds TL1A of claim 12, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 503; and wherein the light chain variable region comprises the amino acid of SEQ ID NO: 502.

### Claim 14 (depends on 11)

The antibody or antigen-binding fragment that specifically binds TL1A of claim 11, wherein the heavy chain variable region comprises an amino acid sequence at least about 90% identical to SEQ ID NO: 511; and wherein the light chain variable region comprises an amino acid sequence at least about 90% identical to SEQ ID NO: 510.

### Claim 15 (depends on 14)

The antibody or antigen-binding fragment that specifically binds TL1A of claim 14, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 511; and wherein the light chain variable region comprises the amino acid of SEQ ID NO: 510.

### Claim 16 (depends on 11)

The antibody or antigen-binding fragment that specifically binds TL1A of claim 11, wherein the heavy chain variable region comprises an amino acid sequence at least about 90% identical to SEQ ID NO: 493; and wherein the light chain variable region comprises an amino acid sequence at least about 90% identical to SEQ ID NO: 492.

### Claim 17 (depends on 16)

The antibody or antigen-binding fragment that specifically binds TL1A of claim 16, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 493; and wherein the light chain variable region comprises the amino acid of SEQ ID NO: 492.

### Claim 18 (depends on 11)

The antibody or antigen-binding fragment that specifically binds TL1A of claim 11, wherein the heavy chain variable region comprises an amino acid sequence at least about 90% identical to SEQ ID NO: 501; and wherein the light chain variable region comprises an amino acid sequence at least about 90% identical to SEQ ID NO: 500.

### Claim 19 (depends on 18)

The antibody or antigen-binding fragment that specifically binds TL1A of claim 18, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 501; and wherein the light chain variable region comprises the amino acid of SEQ ID NO: 500.

### Claim 20 (depends on 11)

The antibody or antigen-binding fragment that specifically binds TL1A of claim 11, wherein the heavy chain variable region comprises an amino acid sequence at least about 90% identical to SEQ ID NO: 515; and wherein the light chain variable region comprises an amino acid sequence at least about 90% identical to SEQ ID NO: 514.

### Claim 21 (depends on 20)

The antibody or antigen-binding fragment that specifically binds TL1A of claim 20, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 515; and wherein the light chain variable region comprises the amino acid of SEQ ID NO: 514.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The antibody or antigen-binding fragment that specifically binds TL1A of any one of claims 1 to 21, wherein the antibody binds human TL1A with a stronger affinity compared to the L8 clone, as determined by ELISA, wherein the L8 clone comprises a heavy chain variable region amino acid sequence as set forth by SEQ ID NO: 491, and a light chain variable region amino acid sequence as set forth by SEQ ID NO: 490.

### Claim 23 (depends on 22)

The antibody or antigen-binding fragment that specifically binds TL1A of claim 22, wherein the antibody binds human TL1A with at least a 2-fold stronger affinity compared to the L8 clone, as determined by ELISA, wherein the L8 clone comprises a heavy chain variable region amino acid sequence as set forth by SEQ ID NO: 491, and a light chain variable region amino acid sequence as set forth by SEQ ID NO: 490.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The antibody or antigen-binding fragment that specifically binds TL1A of any one of claims 1 to 23, wherein the antibody or antigen-binding fragment is chimeric or humanized.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The antibody or antigen-binding fragment that specifically binds TL1A of any one of claims 1 to 23, wherein the antibody or antigen-binding fragment is an IgG antibody.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The antibody or antigen-binding fragment that specifically binds TL1A of any one of claims 1 to 25, wherein the antibody or antigen-binding fragment comprises a Fab, F(ab)2, a single-domain antibody, a single chain variable fragment (scFv), or a nanobody.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The antibody or antigen-binding fragment that specifically binds TL1A of any one of claims 1 to 26, comprising a heavy chain constant region comprising an amino acid sequence as set forth by SEQ ID NO: 542 or 543.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The antibody or antigen-binding fragment of any one of claims 1 to 26, comprising a heavy chain constant region comprising an amino acid sequence as set forth by SEQ ID NO: 542.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The antibody or antigen-binding fragment that specifically binds TL1A of any one of claims 1 to 26, comprising a light chain constant region comprising an amino acid sequence as set forth by SEQ ID NO: 544.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The antibody or antigen-binding fragment that specifically binds TL1A of any one of claims 1 to 29, wherein the antibody or antigen-binding fragment thereof inhibits TL1A induced secretion of interferon gamma from T lymphocytes.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

A pharmaceutical composition comprising the antibody or antigen-binding fragment that specifically binds TL1A of any one of claims 1 to 30 and a pharmaceutically acceptable excipient, carrier, or diluent.

### Claim 32 (depends on 31)

The pharmaceutical composition of claim 31, formulated for intravenous administration.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The antibody or antigen-binding fragment that specifically binds TL1A of any one of claims 1 to 30 or the pharmaceutical composition of claim 31 or 32 for use in treating inflammatory bowel disease, Crohn's disease, or colitis.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

A method of treating inflammatory bowel disease, Crohn's disease, or colitis in an individual comprising administering an effective amount of the antibody or antigen-binding fragment that specifically binds TL1A of any one of claims 1 to 30 or the pharmaceutical composition of claim 31 or 32 to the individual, wherein the individual is diagnosed with or suspected of being afflicted with inflammatory bowel disease, Crohn's disease, or colitis.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The antibody or antigen-binding fragment that specifically binds TL1A of any one of claims 1 to 30 or the pharmaceutical composition of claim 31 or 32 for use in preventing or reducing interferon gamma secretion by T lymphocytes.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

A method preventing or reducing interferon gamma secretion by T lymphocytes in an individual comprising administering an effective amount of the antibody or antigen-binding fragment that specifically binds TL1A of any one of claims 1 to 30 or the pharmaceutical composition of claim 31 or 32 to the individual.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

A nucleic acid encoding the antibody or antigen-binding fragment that specifically binds TL1A of any one of claims 1 to 30.

### Claim 38 (depends on 37)

A cell comprising the nucleic acid of claim 37.

### Claim 39 (depends on 38)

The cell of claim 38, wherein the cell is a eukaryotic cell.

### Claim 40 (depends on 38)

The cell of claim 38, wherein the cell is a Chinese Hamster Ovary (CHO) cell.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 38, 39, 40)

A method of preparing an inflammatory bowel disease, Crohn's disease, or colitis treatment comprising incubating a cell of any one of claims 38 to 40 in a culture medium under conditions sufficient to secrete the antibody or antigen-binding fragment that specifically binds TL1A of any one of claims 1 to 30 into the culture medium.

### Claim 42 (depends on 41)

The method of claim 41, further comprising subjecting the culture medium to at least one purification step.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

A method of preparing an inflammatory bowel disease, Crohn's disease, or colitis treatment comprising admixing the antibody or antigen-binding fragment that specifically binds TL1A of any one of claims 1 to 30 and a pharmaceutically acceptable excipient, carrier, or diluent.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

A method of treating a disease or a condition in an individual possessing a risk variant associated with the disease or the condition, the method comprising administering an effective amount of the antibody or antigen-binding fragment that specifically binds TL1A of any one of claims 1 to 30 or the pharmaceutical composition of claim 31 or 32 to the individual possessing the risk variant for the disease or the condition, wherein the disease or the condition comprises at least one of an inflammatory bowel disease (IBD), Crohn's disease (CD), or colitis.

### Claim 45 (depends on 44)

The method of claim 44, wherein the individual possesses a plurality of risk variants.

### Claim 46 (depends on 45)

The method of claim 45, wherein the plurality of risk variants is at least 3, 4, 5, or 10 risk variants.

### Claim 47 (depends on 44, 45, 46)

The method of any one of claims 44 to 46, wherein risk variant or the plurality of risk variants is associated with a subclinical phenotype of the disease or the condition.

### Claim 48 (depends on 44)

The method of claim 44, wherein the disease or the condition is a severe form of the at least one of the IBD, the CD, or the colitis.
